Cargando…

A 78-Year-Old Man with a Pulmonary Embolism Who Developed Skin Necrosis 7 Days After Treatment with the Direct Oral Anticoagulant Factor Xa Inhibitor Apixaban

Patient: Male, 78-year-old Final Diagnosis: Skin necrosis Symptoms: Cough • SOB Medication: — Clinical Procedure: N/A Specialty: Cardiology • Critical Care Medicine • Dermatology • Hematology • General and Internal Medicine • Pharmacology and Pharmacy • Pulmonology OBJECTIVE: Unusual clinical course...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pansuriya, Tusharkumar, Nguyen, Trung, Sadat, Mir Ali, Raza, Syed A., Sarva, Siva T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841692/ https://www.ncbi.nlm.nih.gov/pubmed/33493142 http://dx.doi.org/10.12659/AJCR.929002

Ejemplares similares

Systemic Inflammation-Related Bradycardia in COVID-19
por: Srinivasan, Aswin, et al.
Publicado: (2021)

The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)

ODP151 Hypothyroidism and Cardiac Remodeling in Ischemic Strokes
por: Rashid, Hytham, et al.
Publicado: (2022)

Usefullness of Heparin Calibrated Anti-Xa Activity to Assess Anticoagulant Activity of Apixaban and Rivaroxaban in Emergency Patients Scheduled for Acute Interventions
por: Riahi, Nada, et al.
Publicado: (2023)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti, Vijay V, et al.
Publicado: (2013)

RESPIRATORY FAILURE SECONDARY TO GUILLAIN–BARRÉ SYNDROME IN COVID-19 INFECTION
por: WILSON, BRANDEN, et al.
Publicado: (2021)

Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
por: Wong, Pancras C., et al.
Publicado: (2011)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Aftermath of Apixaban: Atypical Anticoagulation Aftereffect
por: Karki, Bhesh, et al.
Publicado: (2022)

DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban)
por: Ryu, Rachel
Publicado: (2022)

Diabetic Ketoacidosis and Acute Pancreatitis in Covid-19 Setting
por: Srinivasan, Aswin, et al.
Publicado: (2021)

Apixaban Prophylactic Anticoagulation in Patients with Nephrotic Syndrome
por: Van Meerhaeghe, Tess, et al.
Publicado: (2022)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system
por: Jakowenko, Nicholas, et al.
Publicado: (2020)

Assessment of Anti‐Xa activity in patients receiving concomitant apixaban with strong p‐glycoprotein inhibitors and statins
por: Milner, Erin, et al.
Publicado: (2022)

Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban
por: Mezue, Kenechukwu, et al.
Publicado: (2017)

Pituitary Apoplexy in the Setting of Oral Anticoagulation Therapy With Apixaban
por: Rivera-Nieves, Yadiel, et al.
Publicado: (2021)

Spontaneous thoracolumbar epidural hematoma in an apixaban anticoagulated patient
por: Theofanopoulos, Andreas, et al.
Publicado: (2021)

Dual Anticoagulation With Warfarin and Apixaban: A Case Report
por: Parker, Kristen, et al.
Publicado: (2022)

An Inconspicuous Offender: Apixaban-Induced Anticoagulant-Related Nephropathy
por: Shaw, Dylan J, et al.
Publicado: (2023)

Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction
por: Yurista, Salva R., et al.
Publicado: (2020)

A Case of Bilateral Thalamic Infarcts Involving the Artery of Percheron in the Setting of COVID-19
por: Wilson, Branden, et al.
Publicado: (2021)

The Tick-Derived Anticoagulant Madanin Is Processed by Thrombin and Factor Xa
por: Figueiredo, Ana C., et al.
Publicado: (2013)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
por: Carpenter, Elise, et al.
Publicado: (2019)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation
por: Ikeda, Kozue, et al.
Publicado: (2016)

A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation
por: Willekens, Guido, et al.
Publicado: (2021)

Is concomitant aspirin helping novel oral anticoagulants? Focus on apixaban
por: DiNicolantonio, James J, et al.
Publicado: (2014)

Adrenal Hemorrhage in a Patient Anticoagulated with Apixaban with Antiphospholipid Syndrome
por: Sanford, Zachary, et al.
Publicado: (2019)

Anticoagulant activity of apixaban can be estimated by multiple regression analysis
por: Unami, Naoko, et al.
Publicado: (2020)

Long-term Anticoagulation with Apixaban in Patients with Cerebral Venous Thrombosis
por: Bharath, Suman Preet, et al.
Publicado: (2023)

Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
por: Schultz, Nina Haagenrud, et al.
Publicado: (2018)

Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban
por: Anis, Takla R, et al.
Publicado: (2021)

Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?
por: Freyburger, Geneviève, et al.
Publicado: (2015)

Laboratory Assessment of the Anticoagulant Activity of Apixaban in Patients With Nonvalvular Atrial Fibrillation
por: Kyriakou, Elias, et al.
Publicado: (2018)

Sustained resolution of anticoagulation related iron deficiency anemia with the use of apixaban
por: Choo, Alex, et al.
Publicado: (2019)

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
por: Úlehlová, Jana, et al.
Publicado: (2021)

Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects
por: Ansell, Jack, et al.
Publicado: (2021)

Apixaban-Associated Diffuse Alveolar Hemorrhage in an Elderly Man with Multiple Complications
por: Ozawa, Takuya, et al.
Publicado: (2022)

Bedside anti-Xa measurement for therapeutic assessment of a prophylactic anticoagulation regimen
por: Dewulf, B, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_c7a09vb1tnalg3r8h5m9vto1k4